Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT02152761
Phase
PHASE2
Status
Completed

Conditions

  • Muscle Wasting (Atrophy) After Hip Fracture Surgery

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bimagrumab — DRUG
    Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
  • placebo — OTHER
    Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.

Study Details

The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.

Key Dates

Start date
Sep 16, 2014
Status verified
Aug 2020
Primary completion
May 14, 2018
Completion
Oct 25, 2018

Study Design

Enrollment
251 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: bimagrumab 700 mg
    Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20
  • Experimental: bimagrumab 210 mg
    Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20
  • Placebo Comparator: placebo
    Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria received matching placbo administered via intravenous infusion starting Day 1 until Week 20
  • Experimental: Bimagrumab 70 mg
    Approximately 35 patients who met all inclusion criteria and none of the exclusion criteria were treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20

Primary Outcome Measure

Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24 [ Time Frame: baseline, weeks 12 and 24 ]

Locations (6)

FacilityCityStateZIPSite coordinators
Novartis Investigative SitePhoenixArizona85023-
Novartis Investigative SiteEl CajonCalifornia92020-
Novartis Investigative SiteDenverColorado80210-
Novartis Investigative SiteGainesvilleGeorgia30501-
Novartis Investigative SiteRochesterMinnesota55905-
Novartis Investigative SiteNew YorkNew York10021-

Find similar trials in Phoenix, AZ